Summary:
To assess the impact of additional LDL-cholesterol reduction on major cardiovascular events when an investigational drug administered subcutaneously is used in combination with statin therapy in patients with clinically evident cardiovascular disease.
Inclusion Criteria:
•Male or female between 40 and 80 years of age
•History of clinically evident cardiovascular disease at high risk for a recurrent event
Exclusion Criteria:
•NYHA class III or IV, or last known left ventricular ejection fraction <30%
•Uncontrolled hypertension
•Uncontrolled or recurrent ventricular tachycardia
•Uncontrolled hyperthyroidism or hypothyroidism
•Pregnant or breastfeeding
Qualified Participants May Receive:
The study drug as well as all research-related tests, procedures and visits will be provided at no cost to the subject and their insurance.
Additionally, the subject will receive $50 for each scheduled clinic visit completed. The subject will not be charged for parking while attending study visits.